Isolated Central Nervous System Relapse in a Patient with FLT3-ITD Positive Acute Promyelocytic Leukemia

Clinical Laboratory
|August 8, 2025
PubMed
Abstract

Insights

Central nervous system (CNS) relapse in acute promyelocytic leukemia (APL), especially with FLT3-ITD mutations, requires vigilance. Early diagnosis via imaging and CSF analysis, followed by intrathecal chemotherapy, improves outcomes.

Area of Science:

  • Hematology
  • Oncology
  • Neurology

Background:

  • Acute promyelocytic leukemia (APL) is a distinct subtype of acute myeloid leukemia.
  • While manageable, CNS relapse is a rare but severe complication, particularly in high-risk FLT3-ITD mutated APL.
  • CNS involvement complicates APL treatment and necessitates prompt management.

Observation:

  • A 60-year-old male with FLT3-ITD positive APL developed CNS relapse.
  • Diagnostic workup included MRI and cerebrospinal fluid (CSF) analysis via next-generation sequencing and flow cytometry.
  • MRI showed leptomeningeal thickening and enhancement; CSF confirmed abnormal promyelocytes.

Findings:

  • Leptomeningeal involvement was suggested by MRI findings.
  • Abnormal promyelocytes were detected in CSF via cytology and flow cytometry.
  • Intrathecal chemotherapy resulted in clinical improvement, including headache reduction.

Implications:

  • CNS relapse in APL demands high clinical suspicion, especially with FLT3-ITD mutations.
  • Early diagnosis through imaging and CSF analysis is critical for effective management.
  • Prompt intrathecal therapy is crucial for improving outcomes in high-risk APL patients with CNS relapse.

Related Concept Videos